CDC, NIH, FDA lead­ers call for US-based clin­i­cal tri­al of small­pox drug in treat­ing mon­key­pox

With the ris­ing num­ber of mon­key­pox cas­es, lead­ing re­searchers at the CDC, FDA and NIH are call­ing on a ran­dom­ized clin­i­cal tri­al to see if an ap­proved small­pox drug is ef­fec­tive at treat­ing mon­key­pox.

No mon­key­pox treat­ments are ap­proved in the US, so pa­tients look­ing to get re­lief for their le­sions and oth­er symp­toms from the virus must go through a set of hur­dles to get the small­pox drug through a gov­ern­ment ex­pand­ed ac­cess pro­gram. Ap­proved for small­pox in 2018, the drug is mar­ket­ed as TPOXX by the biotech SIGA. The Eu­ro­pean Union ap­proved it for mon­key­pox in ad­di­tion to small­pox ear­li­er this year and the UK fol­lowed suit in Ju­ly.

In an opin­ion piece pub­lished in the New Eng­land Jour­nal of Med­i­cine on Wednes­day, gov­ern­ment re­searchers said the NIH’s Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases is work­ing with the AIDS Clin­i­cal Tri­als Group, which has over­seen stud­ies of HIV meds since the 1980s, to set up a clin­i­cal tri­al to test TPOXX for mon­key­pox.

But while NI­AID, ACTG and SIGA all con­firmed to End­points News via email that a US-based clin­i­cal tri­al of the drug is be­ing planned, they de­clined to say when it would start. Ac­tivists ar­gue the tri­al should have tak­en place be­fore mon­key­pox be­came a glob­al out­break be­cause the virus has been en­dem­ic in some coun­tries in Africa for years.

“Adults with mon­key­pox in­fec­tion, in­clud­ing peo­ple liv­ing with HIV, would be el­i­gi­ble to en­roll. NI­AID will share more in­for­ma­tion as it be­comes avail­able,” the NI­AID said in an emailed state­ment.

“Those tri­als should have been ob­vi­ous­ly planned for well be­fore a cur­rent out­break. This is what the job of pan­dem­ic pre­pared­ness is. We ob­vi­ous­ly had mil­lions of dos­es stock­piled for this pur­pose and it is in­sane that the fed­er­al gov­ern­ment didn’t ac­tu­al­ly have ef­fi­ca­cy tri­als planned for it,” James Krel­len­stein, strat­e­gy & pol­i­cy man­ag­ing di­rec­tor for the or­ga­ni­za­tion PrEP4All, told End­points in a phone in­ter­view.

The re­searchers analo­gize the lack of ap­proved meds for the cur­rent mon­key­pox out­break to the ear­ly years of the HIV epi­dem­ic in the 1980s, when ther­a­pies had been de­vel­oped, but the process for ap­prov­ing their use in hu­mans was “painful­ly slow.” An eth­i­cal bal­ance was need­ed to en­sure pa­tients had ac­cess while al­so “up­hold­ing the re­spon­si­bil­i­ty” of en­sur­ing they were safe and ef­fec­tive, the re­searchers wrote Wednes­day in NE­JM.

“Now, 34 years lat­er, we are faced with an un­can­ni­ly sim­i­lar sit­u­a­tion,” they wrote. The au­thors of the piece in­clude John Brooks, CMO for the CDC’s Di­vi­sion of HIV Pre­ven­tion; De­bra Birnkrant, di­rec­tor of the Di­vi­sion of An­tivi­rals with­in the FDA’s Cen­ter for Drug Eval­u­a­tion and Re­search; and Pe­ter Kim, deputy di­rec­tor of the Ther­a­peu­tic Re­search Pro­gram in the Di­vi­sion of AIDS at NI­AID.

Or­ga­ni­za­tions such as PrEP4All have called for the re­moval of re­stric­tions to the drug so pa­tients can get the med quick­er and more eas­i­ly as mon­key­pox case counts climb past 25,000 across 83 coun­tries. The US is one of the biggest out­break re­gions and three states — Illi­nois, New York and Cal­i­for­nia — have de­clared it a pub­lic health emer­gency.

Pri­or to the cur­rent glob­al out­break, the NIH had be­gun plan­ning for a ran­dom­ized clin­i­cal tri­al of the drug in the De­mo­c­ra­t­ic Re­pub­lic of the Con­go, but in their NE­JM piece, the re­searchers cite the need for a US-based tri­al since cur­rent world­wide cas­es are of a dif­fer­ent clade than what is seen in the DRC.

The US has ac­cess to about 1.7 mil­lion cours­es of the drug through the Strate­gic Na­tion­al Stock­pile, and BAR­DA has a con­tract with SIGA to re­plen­ish the cours­es when they ex­pire, ac­cord­ing to the com­pa­ny. As of last week, 10,000 cours­es of the drug had been sent to states and cities up­on re­quest, the De­part­ment of Health and Hu­man Ser­vices told NPR.

A SIGA spokesper­son said the com­pa­ny is “aware of the plans for a clin­i­cal tri­al and is work­ing with NI­IAD [sic] to ad­vance a place­bo-con­trolled study of tecovir­i­mat in the treat­ment of mon­key­pox.” SIGA re­ports quar­ter­ly earn­ings on Thurs­day.

SIGA can­celed a sched­uled in­ter­view be­tween sci­ence chief Den­nis Hru­by, CEO Phillip Gomez and End­points, say­ing that it “would pre­fer to wait for pub­li­ca­tion of the full ar­ti­cle in NE­JM be­fore com­ment­ing much fur­ther on any specifics.”

Hru­by told NBC News last month that plans for large clin­i­cal tri­als were in ad­vanced stages in Cana­da, the UK and the EU. Hru­by told the news out­let that SIGA might not re­ly on US tri­al da­ta to sub­mit to the FDA, but rather look to com­bined find­ings in oth­er coun­tries and safe­ty da­ta from glob­al com­pas­sion­ate-use pro­grams.

In their NE­JM piece, the CDC, FDA and NIH re­searchers wrote that they “an­tic­i­pate that these tri­als will pro­vide da­ta need­ed for clin­i­cal and reg­u­la­to­ry de­ci­sion mak­ing in the Unit­ed States.”

SIGA’s drug was ap­proved in the US in 2018 un­der the “An­i­mal Rule,” which al­lows drugs for se­ri­ous or life-threat­en­ing con­di­tions to be green­lit when hu­man stud­ies are deemed un­eth­i­cal. Ef­fi­ca­cy is es­tab­lished in an­i­mal mod­els of the hu­man dis­ease. The drug was ap­proved based on ef­fi­ca­cy da­ta gath­ered from in­fect­ing non­hu­man pri­mates with mon­key­pox virus and rab­bits with rab­bit­pox virus, as well as safe­ty da­ta from more than 400 healthy adult vol­un­teers.

As the mon­key­pox out­break spreads to more than 6,000 re­port­ed cas­es in the US, peo­ple at high­est risk have been scram­bling to get vac­ci­nat­ed against the virus. There is one jab ap­proved in the US, Bavar­i­an Nordic’s Jyn­neos, which is in lim­it­ed sup­plies in the US af­ter a na­tion­al stock­pile large­ly evap­o­rat­ed in re­cent years. A small­pox vac­cine, ACAM2000, is al­so be­ing used in cer­tain in­stances.

Mean­while, Mod­er­na lead­ers said Wednes­day that the pan­dem­ic-in­fa­mous biotech is look­ing in­to a po­ten­tial mon­key­pox pro­gram.

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Dave Marek, Myovant CEO

My­ovant board balks as ma­jor­i­ty own­er Sum­it­o­mo swoops in with a $2.5B deal to buy them out

Three years after Sumitomo scooped up Roivant’s 46% stake in the publicly traded Myovant $MYOV as part of a 5-company, $3 billion deal, they’re coming back for the whole thing.

But these other investors at Myovant want more than what the Japanese pharma company is currently offering to pay at this stage.

Sumitomo is bidding $22.75 a share for the outstanding stock, which now represents 48% of the company after Sumitomo bumped its ownership since the original deal with Roivant. Myovant, however, created a special committee on the board, and they’re shaking their heads over the offer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric, Biohaven CEO

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

What’s Biohaven without its CGRP portfolio? That’s what CEO Vlad Coric is tasked with deciding as he maps out the new Biohaven post-Pfizer takeover.

Pfizer officially scooped up Biohaven’s CGRP assets on Monday, including blockbuster migraine drug Nurtec and the investigational zavegepant, for $11.6 billion. As a result, Coric spun the broader pipeline into an independent company on Tuesday — with the same R&D team behind Nurtec but about 1,000 fewer staffers and a renewed focus on neuroscience and rare disease.

In AstraZeneca's latest campaign, wild eosinophils called Phils personify the acting up often seen in uncontrolled asthma

As­traZeneca de­buts an­noy­ing pur­ple ‘Phil’ crea­tures, per­son­i­fied asth­ma eosinophils ‘be­hav­ing bad­ly’

There are some odd-looking purple creatures lurking around the halls of AstraZenca lately. The “Phil” character cutouts are purple, personified eosinophils with big buggy eyes and wide mouths, and they’re a part of AZ’s newest awareness effort to help people understand eosinophilic asthma.

The “Asthma Behaving Badly” characters aren’t only on the walls at AZ to show the new campaign to employees, however. The “Phils” are also showing up online on the campaign website, and in digital and social ads and posts on Facebook and Instagram.

Big Phar­ma heavy­weights seek tweaks to FDA's clin­i­cal out­come as­sess­ment guid­ance

Pfizer, GSK, Janssen, Regeneron, Boehringer Ingelheim and at least a half dozen other companies are calling on the FDA to provide significantly more clarity in its draft guidance from this summer on clinical outcome assessments, which are a type of patient experience.

The draft is the third in a series of four patient-focused drug development guidance documents that the FDA had to create as part of the 21st Century Cures Act, and they describe how stakeholders (patients, caregivers, researchers, medical product developers and others) can collect and submit patient experience data and other relevant information for medical product development and regulatory decision-making.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Rob Etherington, Clene CEO

Star­tup's gold nanocrys­tal ALS drug flops a PhII tri­al, a re­minder of the dis­ease's ob­sta­cles de­spite Amy­lyx OK

Despite the FDA approving an ALS drug for the first time in five years last week, the disease continues to fluster researchers, and another biotech is feeling the pain of a mid-stage failure.

Clene Nanomedicine reported early Monday that its ALS program, which uses gold nanocrystals to try to catalyze intracellular reactions, did not achieve its Phase II primary or secondary endpoints. And in a press release, the company noted for the first time that it’s speaking with “potential strategic partners” about the program — language that typically indicates a biotech is preparing to sell off an asset.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Robert Califf, FDA commissioner (via AP Images)

User fees in ac­tion: FDA un­veils new short­ened sup­ple­ment re­view, rare dis­ease pi­lots

Thanks to PDUFA VII, signed into law last Friday by President Joe Biden, the FDA this week unveiled two new industry-friendly pilot programs to advance new rare disease endpoints via additional meetings, and to shorten FDA review times for supplemental apps aimed at unmet medical needs.

The agency this week released eagerly-awaited details behind the shortened pilot, known as the Split Real Time Application Review or STAR pilot program, which will speed up certain FDA reviews of efficacy supplements across all therapeutic areas (thanks to earlier submissions of data), but only for those that propose addressing an unmet medical need.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.

Mar­ket­ingRx roundup: No­var­tis re­cruits NFL coach for Leqvio cam­paign; Pfiz­er pro­motes ‘Sci­ence’ merch on so­cial me­dia

Novartis is turning to a winning coach to talk about Leqvio and the struggles of high cholesterol — including his own. Bruce Arians, the retired NFL head coach of the Arizona Cardinals and Super Bowl-winning Tampa Bay Buccaneers, is partnering with the pharma for its “Coaching Cholesterol” digital, social and public relations effort.

In the campaign, Arians talks about the potential for “great comebacks” in football and heart health. Once nicknamed a “quarterback whisperer,” he is now retired from fulltime coaching (although still a front-office consultant for Tampa Bay), and did a round of media interviews for Novartis, including one with People and Forbes.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,400+ biopharma pros reading Endpoints daily — and it's free.